International Trade in Biotechnology Products and Strategic Mandatory Labelling
This paper examines strategic motives to impose mandatory labelling of biotechnology products when consumers perceive these products as being of lower quality. When a foreign dominant firm produces a biotechnology product, it is shown that without mandatory labelling fringe firms, which produce a conventional product, provide voluntary labelling as long as voluntary labelling is fully credible. Information on which product is biotechnologically engineered is hence completely disclosed without mandatory labelling. An importing country may nevertheless impose mandatory labelling mainly because part of labelling cost can be shifted to the foreign dominant firm. Strategic mandatory labelling, however, is not always protectionist.
|Date of creation:||Apr 2003|
|Note:||This version: January 30, 2003|
|Contact details of provider:|| Phone: +81-42-580-8000|
Web page: http://www.econ.hit-u.ac.jp/
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:hit:econdp:2003-01. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Digital Resources Section, Hitotsubashi University Library)
If references are entirely missing, you can add them using this form.